Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.
Mural Oncology PLC (MURA) is a clinical-stage biotech company pioneering engineered cytokine therapies for cancer treatment. This page aggregates official announcements, clinical trial updates, and strategic developments related to their innovative immuno-oncology pipeline.
Investors and researchers will find timely updates on key programs including nemvaleukin (IL-2 fusion protein), IL-18, and IL-12 therapies. Content spans regulatory milestones, partnership announcements, financial disclosures, and scientific presentations - all essential for understanding the company's progress in redefining cytokine-based cancer treatments.
Our curated news collection enables efficient tracking of material events including clinical trial initiations, data readouts, and intellectual property developments. The resource is particularly valuable for monitoring advancements in protein-engineered therapies designed to enhance antitumor immunity while reducing systemic toxicity.
Bookmark this page for consolidated access to Mural Oncology's latest developments in immuno-oncology research and clinical translation. Check regularly for updates on novel therapeutic approaches that combine cytokine biology with precision engineering.
Mural Oncology (Nasdaq: MURA) has announced the discontinuation of all clinical development of nemvaleukin alfa following unsuccessful trial results. The decision comes after reviewing data from the phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer.
The company reported $144.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024. In response to these developments, Mural plans to:
- Reduce its workforce by approximately 90%
- Explore strategic alternatives to maximize shareholder value
- Engage Lucid Capital Markets, as financial advisor
The ARTISTRY-6 trial's cohort 2, involving 92 patients with mucosal melanoma, failed to achieve its primary endpoint. Additionally, cohort 3, testing less-frequent intravenous dosing in cutaneous melanoma patients, showed insufficient activity to warrant continuation.
Mural Oncology (MURA) announced the discontinuation of its Phase 3 ARTISTRY-7 trial evaluating nemvaleukin alfa in combination with KEYTRUDA® for platinum-resistant ovarian cancer (PROC). The decision came after interim analysis showed no statistically significant improvement in overall survival compared to chemotherapy.
The combination therapy achieved a median overall survival of 10.1 months versus 9.8 months for chemotherapy (hazard ratio: 0.98). Despite the setback in PROC treatment, nemvaleukin maintained a favorable safety profile across its clinical program, which has treated over 800 patients.
The company will continue its Phase 2 ARTISTRY-6 trial in mucosal melanoma, with topline results expected in Q2 2025. Additional data readouts for less-frequent intravenous dosing in cutaneous melanoma patients are anticipated in Q2 2025 for monotherapy (cohort 3) and H2 2025 for combination therapy (cohort 4).
Mural Oncology (NASDAQ: MURA) announced Q4 and full-year 2024 financial results, highlighting key upcoming clinical milestones. The company expects several significant data readouts in 2025, including the interim analysis of the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer (late Q1/early Q2 2025) and top-line data from ARTISTRY-6 in mucosal melanoma (Q2 2025).
Financial highlights include:
- Cash position of $144.4 million as of December 31, 2024
- Q4 2024 R&D expenses decreased to $28.7 million from $42.2 million in Q4 2023
- Q4 2024 G&A expenses reduced to $7.2 million from $16.3 million in Q4 2023
- Net loss of $34.3 million in Q4 2024, improved from $59.5 million in Q4 2023
The company expanded its pipeline with two new development candidates: MURA-8518 (IL-18 program) and MURA-7012 (IL-12 program). Current cash runway is expected to fund operations into Q1 2026.
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. CEO Caroline Loew, Ph.D., will deliver a presentation on March 4, 2025, at 3:10 p.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website at ir.muraloncology.com/events-and-presentations. For those unable to attend the live session, a recorded version will be made available for later viewing on the same platform.
Mural Oncology (MURA) announced key milestones and pipeline updates, with significant catalysts expected throughout 2025. The company reached 75% of overall survival events for its ARTISTRY-7 trial, evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer, with interim data expected in late Q1/early Q2 2025.
Two new development candidates were nominated: MURA-8518, a novel IL-18 therapy, and MURA-7012, targeting IL-12 pathways. The company plans an IND submission for MURA-8518 in Q4 2025. Additional readouts include ARTISTRY-6 trial data for mucosal melanoma in Q2 2025, and preliminary data for less-frequent intravenous dosing in cutaneous melanoma patients in 1H and 2H 2025.
Through operational efficiencies, Mural has extended its cash runway into Q1 2026, positioning itself to advance through these key upcoming catalysts.
Mural Oncology announced equity grants to four new employees as inducement awards under Nasdaq Rule 5635(c)(4). The grants include 26,300 stock options and 13,200 restricted stock units. The stock options were granted at $4.18 per share, matching Nasdaq's closing price on December 2, 2024.
The options have a ten-year term with a four-year vesting schedule: 25% vests after one year, followed by quarterly vesting of 6.25%. The restricted stock units vest over four years at 25% annually. Both grants are subject to continued employment and the company's 2024 Inducement Stock Option and Incentive Plan.
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab. The trial, involving 286 patients across 32 sites, demonstrated a 10% overall response rate in monotherapy and 13% in combination therapy. Notable results included a 21% response rate in platinum-resistant ovarian cancer (PROC) patients and 33.3% in mucosal melanoma patients. The treatment was generally well-tolerated with manageable side effects. Data readouts from two ongoing registrational trials are expected in Q1/Q2 2025.
Mural Oncology (NASDAQ: MURA) reported Q3 2024 financial results and pipeline updates. The company completed enrollment in two key trials: ARTISTRY-7 (456 patients) for platinum-resistant ovarian cancer and ARTISTRY-6 Cohort 2 (92 patients) for mucosal melanoma, with data readouts expected in late Q1/early Q2 2025 and Q2 2025, respectively. Financial highlights include cash position of $175.5M, R&D expenses of $27.6M (down from $40.4M in Q3 2023), and net loss of $31.8M (improved from $51.3M in Q3 2023). The company expects its current cash runway to extend into Q4 2025.
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference for one-on-one meetings on November 19-20, 2024, and the Piper Sandler 36th Annual Healthcare Conference for a fireside chat on December 9, 2024, at 9:30 a.m. ET. Key management team members participating include CEO Caroline Loew, Chief Medical Officer Vicki Goodman, and CFO Adam Cutler. A webcast of the Piper Sandler presentation will be available on the company's investor relations website.
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune responses and tumor growth inhibition, with candidate nomination expected by end of 2024 and IND submission in Q4 2025. The company's IL-12 program demonstrated potential to mitigate cytokine toxicity, with candidate nomination planned by end of 2024. Two late-stage trials, ARTISTRY-7 for platinum-resistant ovarian cancer and ARTISTRY-6 for mucosal melanoma, expect data readouts in late Q1/early Q2 2025 and Q2 2025, respectively.
